Comparative Pharmacology
Head-to-head clinical analysis: FUNGIZONE versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNGIZONE versus NILSTAT.
FUNGIZONE vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability, leading to leakage of intracellular contents and cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
IV: 0.25-1 mg/kg/day as a single infusion; for aspergillosis, up to 1.5 mg/kg/day; maximum daily dose 1.5 mg/kg.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 15 days (range 10-20 days) after a single dose; with prolonged therapy, a prolonged terminal half-life of up to 15 days reflects slow redistribution from tissue depots.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Primarily fecal (40-50%) via biliary elimination without metabolism; renal excretion of unchanged drug is minimal (<5% in 24 hours).
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category C
Category C
Antifungal
Antifungal